WallStreetZenWallStreetZen

NASDAQ: PBYI
Puma Biotechnology Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Puma Biotechnology earnings were $30.3M for the trailing 12 months ending Dec 31, 2024, with 34.8% growth year over year. The latest PBYI earnings report on Dec 31, 2024 announced Q4 2024 earnings of $19.3M, down 5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PBYI reported annual earnings of $30.3M, with 40.2% growth. The next PBYI earnings date is Apr 30, 2025.

PBYI past earnings growth

How has PBYI's earnings growth performed historically?

Company
34.78%
Industry
11.8%
Market
63.03%
PBYI's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PBYI's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
PBYI's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

PBYI earnings history

Current Revenue
$230.5M
Current Earnings
$30.3M
Current Profit Margin
13.1%

PBYI Return on Equity

Current Company
46.1%
Current Industry
-2%
Current Market
34.1%
PBYI's Return on Equity (46.1%)... subscribe to Premium to read more.
High Return on Equity Performance

PBYI undefined

Current Company
14.2%
Current Industry
-0.4%
PBYI is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PBYI announces earnings.

PBYI undefined

Current Company
31.18%
Current Industry
5.9%
PBYI has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PBYI vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PBYI$48.08M$30.28M+34.78%$0.62
FDMT-$154.16M-$160.87MN/A-$2.98
IKT-$27.49M-$27.52MN/A-$1.16
TARA-$44.26M-$44.60MN/A-$2.17
FENC$4.00M-$436.00kN/A-$0.02
View Top Biotech Stocks

PBYI earnings dates

Next earnings date
Apr 30, 2025

Puma Biotechnology Earnings Reports & History FAQ

What were Puma Biotechnology's earnings last quarter?

On PBYI's earnings call on Invalid Date, Puma Biotechnology (NASDAQ: PBYI) reported Q4 2024 earnings per share (EPS) of $0.39, up 50% year over year. Total PBYI earnings for the quarter were $19.31 million. In the same quarter last year, Puma Biotechnology's earnings per share (EPS) was $0.26.

If you're new to stock investing, here's how to buy Puma Biotechnology stock.

When does Puma Biotechnology report earnings?

The next PBYI earnings call is Invalid Date. Add PBYI to your watchlist to be reminded of Puma Biotechnology's next earnings date.

Is Puma Biotechnology profitable or losing money?

As of the last Puma Biotechnology earnings report, Puma Biotechnology is currently profitable. Puma Biotechnology's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $30.28 million, a 40.23% increase year over year.

What was PBYI's earnings growth in the past year?

As of Puma Biotechnology's earnings date in Invalid Date, Puma Biotechnology's earnings has grown 34.78% year over year. This is 22.98 percentage points higher than the US Biotechnology industry earnings growth rate of 11.8%. PBYI earnings in the past year totalled $30.28 million.

What are Puma Biotechnology's earnings expectations?

The current EPS estimate for Puma Biotechnology's earnings report in Invalid Date is -$0.22.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.